{"disease":{"id":"panuveitis","name":"panuveitis"},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02595398","title":"Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT03339102","title":"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02746991","title":"Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04521673","title":"Pathogen Detection in Infectious Uveitis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03097315","title":"Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT05953688","title":"POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Alumis Inc","has_results":false},{"nct_id":"NCT02952001","title":"MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301","phase":"","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT01526889","title":"Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06085079","title":"Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Massachusetts Eye Research and Surgery Institution","has_results":false},{"nct_id":"NCT04126850","title":"Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Fakultas Kedokteran Universitas Indonesia","has_results":false},{"nct_id":"NCT03656692","title":"Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Mallinckrodt","has_results":true},{"nct_id":"NCT05101928","title":"Ozurdex Monotherapy Trial","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}